stockrowWhat it does
Elanco makes products that prevent and treat disease in pets and farm animals. Its customers include veterinarians, pet owners, livestock producers, distributors and retailers. The company sells products in more than 90 countries and operates as a single animal health segment.
For dogs and cats, Elanco sells products for parasites, skin conditions, pain and vaccination. Its flea and tick products include the Advantage Family and Seresto, which are available over the counter, and the prescription Credelio Family. Zenrelia is an oral treatment for itching and atopic dermatitis in dogs. Galliprant treats pain and inflammation associated with osteoarthritis in dogs.
For livestock, Elanco sells products used in cattle, poultry, swine and sheep. These include vaccines, antibiotics, feed additives, insecticides and enzymes. Rumensin helps improve feed and milk production efficiency in cattle, while Maxiban and Monteban help prevent an intestinal disease in broiler chickens. Experior reduces ammonia emissions from cattle or their waste.
Elanco is headquartered in Indianapolis, Indiana. Jeffrey Simmons is its president and chief executive officer. The company develops products internally and with partners, and also obtains products through licenses or acquisitions.
How it makes money
Elanco earns revenue primarily by selling animal health products through distributors, retailers and veterinarians, and directly to farm animal producers. It operates one reportable segment, although it reports revenue by animal category.
The reportable segment generated $4.7 billion of revenue in FY2025. Pet Health generated $2.3 billion, or 48.8% of revenue, while cattle products generated $1.1 billion. Poultry products generated $858.0 million and swine products generated $379.0 million.
Pet Health sales include both prescription medicines and over-the-counter products. Its portfolio ranges from flea and tick collars and chewable parasite treatments to vaccines and medicines for skin conditions and pain. Farm Animal sales include products for disease prevention and treatment, food safety, efficiency and sustainability. The Advantage Family, Seresto, Credelio Family, Rumensin and Maxiban / Monteban together represented approximately 38% of total revenue in 2025.
Many products are sold throughout the year, but demand for certain pet parasite treatments is seasonal. In 2025, approximately 70% of Seresto revenue and 60% of Advantage Family revenue occurred in the first half, reflecting Northern Hemisphere flea and tick season. Some treatments, such as Credelio Quattro, are administered regularly: Quattro is a monthly chewable tablet for dogs.
Elanco competes on price as well as product quality, cost-effectiveness and differentiation. In Q2 2026, it reported 8% organic constant currency revenue growth, with contributions from both price and volume.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Pet Health | $2.3 billion | 48.8% | 7.33% |
| Cattle | $1.1 billion | 23.9% | 11.7% |
| Poultry | $858.0 million | 18.2% | 7.79% |
| Swine | $379.0 million | 8.04% | 3.55% |
| Contract Manufacturing and Other | $53.0 million | 1.12% | 15.2% |
| Aqua | $0.00 | 0.00% | −100.0% |
Customers and how it sells
Elanco primarily sells pet health products to third-party distributors and retailers, and directly to veterinarians, who typically resell them to pet owners. Its farm animal products go mainly to distributors and directly to beef, dairy, pork and poultry producers. Products reach customers through veterinary clinics, retail stores and e-commerce.
The company uses its sales representatives and veterinary consultants to provide product information, scientific consulting and education. Its global sales force had over 2,200 sales representatives. Certain pet products, including the Advantage Family and Seresto, are sold through both veterinary and retail channels.
The largest customer, an affiliate of Cencora, Inc., is a veterinary distributor. In 2026, Elanco added Costco and Dollar General as customers, expanding in-store availability for Seresto and the Advantage Family.
The United States generated $2.2 billion of revenue in FY2025, or 47.4% of the total. International operations generated $2.5 billion, or 52.6%. Brazil, the United Kingdom and China were Elanco’s largest markets outside the United States by total revenue.
| Region | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| International | $2.5 billion | 52.6% | 3.25% |
| United States | $2.2 billion | 47.4% | 9.72% |
Suppliers and costs
Elanco manufactures products at its own facilities and through contract manufacturers. Its network included 16 company-operated manufacturing sites and approximately 140 contract manufacturing organizations. The company expected to close its Kansas City manufacturing facility by the end of 2026 under its restructuring plan.
Elanco buys raw materials and active pharmaceutical ingredients from third-party suppliers and manufacturers. It generally maintains two sources for key ingredients supporting its highest-value brands, but some raw materials, intermediates and active ingredients come from a single source. Active ingredients for biologic products are made primarily in Elanco’s facilities, while chemically derived ingredients come from external partners. The company uses inventory management to support supply when sources are limited.
Research and development expense was $368 million in 2025. Manufacturing changes can require capital spending, process modifications and regulatory approvals. Elanco also invests in marketing for product launches. In Q2 2026, the company said inflation remained above historical levels and planned to continue investing in direct-to-consumer marketing.
- Revenue$4.7B
- Cost of revenue−$2.1B
- Research and development−$368.0M
- Selling, general and administrative−$1.4B
- Other operating costs−$780.0M
- Operating income$15.0M
Competitive position
Elanco competes globally with animal health medicines and vaccines companies, including Zoetis, Boehringer Ingelheim Animal Health and Merck Animal Health. It also faces generic drug manufacturers and nutritional health product producers. Competition varies by region, animal species and product. Elanco competes on quality, price, cost-effectiveness, promotion, product development and differentiation.
The company relies on patents, trademarks, trade secrets and regulatory exclusivity to protect its products. Its portfolio had approximately 7,000 patents and applications. Some products, including certain Advantage Family products, Rumensin and Maxiban / Monteban, do not have patent protection. The U.S. formulation patent for Seresto expires in September 2027.
Our reading: Intellectual property provides product-specific protection, but its strength varies because some established products lack patents and others face expirations. Our reading: Elanco’s veterinary relationships and access to both retail and clinic channels support distribution, though competing products and promotion can still pressure sales and prices.
Elanco said Zenrelia had reached approximately 18,000 U.S. veterinary clinics in June 2026 despite new competition. It also said Credelio Quattro was carried by over half of the U.S. veterinary clinic base in Q2 2026.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Zoetis Inc. | Animal health medicines and vaccines | High |
| Boehringer Ingelheim Animal Health GmbH | Animal health medicines and vaccines | High |
| Merck Animal Health | Animal health medicines and vaccines | High |
Growth opportunities
Elanco seeks growth by developing new products, extending existing products to additional uses and species, and expanding their geographic reach. It develops products internally and with partners, and uses licenses and acquisitions to add to its portfolio.
In Q2 2026, Elanco reported $340 million of innovation revenue and raised its 2026 innovation revenue target to approximately $1.25 billion. It expects organic constant currency revenue growth of 6% to 7% for the year. The company said Zenrelia was the largest contributor to its second-quarter growth, followed by Credelio Quattro.
Elanco launched the canine dermatology treatment Befrena in May 2026 and said it was increasing supply to meet demand. The company expects supply to reach unconstrained levels in early 2027. It also launched Credelio Quattro in Australia, Canada and Japan in 2026, with the European Union and United Kingdom next in its expansion plans.
In farm animals, Elanco is investing in Bovaer, a methane-reducing feed ingredient for lactating dairy cattle. The company said Bovaer grew year over year in Q2 2026 from a small base. Elanco also expects its Experior cattle product to continue growing, although it anticipates moderating growth rates against more difficult comparisons.
- $4.8BFY2021
- $4.4BFY2022
- $4.4BFY2023
- $4.4BFY2024
- $4.7BFY2025
- $5.1BFY2026 guidance
Structural risks
- Product concentration: Elanco’s results depend on its top products. Its five largest products or product families represented approximately 38% of total revenue in 2025; competition or changes affecting those products could reduce sales.
- Competition and patent expiry: New branded or generic products may offer ease-of-use, therapeutic or cost advantages, resulting in lower sales or prices. Patent protection for some products has expired or will expire over the next several years.
- Supply and manufacturing: Elanco relies on outside manufacturers and suppliers, including single sources for some materials and ingredients. Shortages, quality problems or regulatory delays can interrupt supply, and adding manufacturing capacity can take time and require approvals.
- Debt: Elanco has substantial indebtedness. Its debt can limit financing and strategic flexibility, while certain credit facilities contain operating and financial restrictions.
- Regulation and product development: Animal health products require country-specific approvals and ongoing monitoring. Elanco’s future growth depends on its new-product pipeline and management of existing products, including additional registrations and indications.
Bottom line
Our reading
Our reading: Elanco combines a pet medicines business with products used by livestock producers, reaching both through distributors and direct customer relationships (item1). Its growth depends in part on expanding newer products such as Zenrelia and Credelio Quattro, while established brands remain exposed to competition and patent expiry (item1; call_prepared). Manufacturing dependencies and substantial debt add constraints alongside those product opportunities (item1; item1a).